About Beam Therapeutics
Beam Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2017 by Keith Joung and David Liu. Developer of gene therapy using CRISPR base editing to treat diseases. Beam Therapeutics has raised $222 million across 4 funding rounds from investors including Sana Biotechnology, Arch Venture Partners and Eight Roads Ventures. The company has 483 employees. Beam Therapeutics has completed 1 acquisition, including GuideTX. Its chief executive, as recorded, is John Evans. Its website beamtx.com draws about 49 thousand monthly visits. Beam Therapeutics offers products and services including Base Editing Technology. Its focus areas include Life Sciences, Gene Therapy, DNA and CRISPR. Its competitors include eGenesis, Korro Bio and Editas Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Beam Therapeutics was founded in 2017 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed using CRISPR base editing technology to address conditions including sickle cell disease, thalassemia, leukemia, liver disorders, and ocular diseases. Specific base pairs in DNA or RNA are targeted and edited to correct point mutations, with operations focused on advancing these treatments through research and development.
- Headquarters Cambridge, United States
- Employees 483
- Founders Keith Joung, David Liu
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website beamtx.com
- Social LinkedIn X
- Legal Name Beam Therapeutics Inc.
- Annual Revenue$139.74 M (USD)120.01as on Dec 31, 2025
- Net Profit-$79.99 M (USD)78.77as on Dec 31, 2025
- EBITDA-$361.4 M (USD)8.19as on Dec 31, 2025
- Total Equity Funding$222M (USD)
in 4 rounds
- Latest Funding Round$50M (USD), Post-IPO
Oct 2021
- InvestorsSana Biotechnology
& 8 more
- Employee Count483
- Investments & Acquisitions
Products & Services of Beam Therapeutics
Beam Therapeutics offers a comprehensive portfolio of products and services, including Base Editing Technology.
Precision tool for modifying DNA bases in genetic therapies
Funding Insights of Beam Therapeutics
Beam Therapeutics has successfully raised a total of $222M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $222M
- Total Rounds 4
- Last Round Post-IPO — $50M
- First Round $87M
(May 2018)
- Investors Count 9
All 4 funding rounds of Beam Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $50M | Post-IPO | – | – | |
| Jan 2021 | Post-IPO | – | – | – | |
| Mar 2019 | $135M | Series B | – | Altitude Life Science Ventures, Google Ventures | |
| May 2018 | $87M | Series A | – | F-Prime Capital, Arch Venture Partners | – |
9 investors in total: 9 institutional.
Investors in Beam Therapeutics
Beam Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Sana Biotechnology, Arch Venture Partners and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage life sciences sectors focused VC firm investing in the US | altitudelsv.com | Kirkland, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital firm | omegafunds.com | Boston, United States | ||
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | sana.com | Seattle, United States | |
| cormorant-asset.com | ||||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States |
Investor details for Beam Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Beam Therapeutics
205 people are tracked at Beam Therapeutics (103 in leadership, 10 in board & advisors, 92 in team); the tracked headcount is 483.
| Name | Role | Group |
|---|---|---|
Keith Joung | Co-Founder | Leadership |
David Liu | Co-Founder | Leadership |
John Evans | CEO | Leadership |
Brian Cafferty | Senior Director | Leadership |
Rahim Merchant | Vp, Head Of Program Management | Leadership |
Giuseppe Ciaramella | President | Leadership |
Arthur Lo | Director - Clinical Pharmacology And Pharmacometrics | Leadership |
Zichuan Zhang | Director, Analytical Development | Leadership |
Galina Craig | Associate Director Clinical Operations | Leadership |
Rodrigo Laureano | Vice President, Head Of Non-clinical Development | Leadership |
Jamie Harrop | Vice President Clinical Operations | Leadership |
Priya S. Chockalingam | Vice President, Head Of Clinical Bioanalytics & Translational Sciences | Leadership |
James Maier | Director, Clinical Operations | Leadership |
Bahru Habtemariam | Vice President, Clinical Pharmacology | Leadership |
Ling Lin | Director Of Clinical Bioanalytics & Translational Science | Leadership |
Sunita Goyal | Senior Vice President Clinical Development | Leadership |
Amy Simon | Chief Medical Officer | Leadership |
Gopi Shanker | Chief Scientific Officer | Leadership |
Susan O’connor | Chief Human Resources Officer | Leadership |
Ajit Kamath | Associate Director Analytical Development | Leadership |
185 more people are available in the full profile.
Complete people profiles for Beam Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Beam Therapeutics
Beam Therapeutics is a publicly listed company on the NASDAQ with ticker symbol BEAM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Feb 2020
- Listed onNASDAQ: BEAM
- Listed entityBeam Therapeutics Inc.
- Exchange sectorHealth technology
- ISINUS07373V1052
- Share price$24.43 (-2.79% on the day) · 2026-10-13
- Market capitalisation$2.52B
- EPS (diluted, trailing year)$-0.86
- Volume (last session)1,667,981
Financials of Beam Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $139.7M | -$80.0M | -$361.4M |
| 2024 | $63.5M | -$376.7M | -$393.6M |
| 2023 | $377.7M | -$132.5M | -$156.5M |
| 2022 | $60.9M | -$289.1M | -$315.9M |
| 2021 | $51.8M | -$370.6M | -$376.0M |
Detailed financial statements for Beam Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beam Therapeutics
Beam Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GuideTX.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Technology for DNA and RNA delivery to targets is provided. | guidetx.com | Tucker, United States | 2019 | Feb 2021 | $120M |
Complete acquisition details for Beam Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Beam Therapeutics
5 dated milestones of Beam Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Beam Therapeutics is founded.
- Funding First funding round of $87.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires GuideTX.
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Beam Therapeutics
Beam Therapeutics has 3 listed competitors in our database, 3 of them funded. They include eGenesis, Korro Bio and Editas Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. |
Detailed competitors of Beam Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Beam Therapeutics
The website of Beam Therapeutics (beamtx.com) receives about 48.5K visits a month and ranks #806,225 among all websites worldwide, #965 in Biotechnology and Pharmaceuticals.
- Monthly visits48.5K
▲ 30.3% vs previous month
- Unique visitors15.9K
per month
- Global rank#806,225
among all websites
- Category rank#965
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.2
- Average visit37 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Beam Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| akebia.com | 100% | 12.7K | #1,972,683 | View details | |
| takedaoncology.com | 98% | 14.3K | #1,943,946 | View details | |
| karyopharm.com | 97% | 11.8K | #3,094,808 | View details | |
| alexion.com | 95% | 81.8K | #498,312 | View details | |
| servier.us | 84% | #2,050,491 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Beam Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Beam Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Beam Therapeutics
Complete news archive for Beam Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beam Therapeutics
Beam Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Beam Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
John Evans is the CEO of Beam Therapeutics, as recorded in our data.
Beam Therapeutics is a funded company, having raised a total of $222M across 4 funding rounds to date. The company's 1st funding round was a Series A of $87M, raised on May 2018.
Beam Therapeutics has 483 employees.
Annual revenue of Beam Therapeutics is $139.74M as on Dec 31, 2025.
Beam Therapeutics was founded in 2017 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed using CRISPR base editing technology to address conditions including sickle cell disease, thalassemia, leukemia, liver disorders, and ocular diseases. Specific base pairs in DNA or RNA are targeted and edited to correct point mutations, with operations focused on advancing these treatments through research and development.
Beam Therapeutics's top competitors include eGenesis, Korro Bio and Editas Medicine.
Beam Therapeutics offers Base Editing Technology.
Yes, Beam Therapeutics is publicly traded on NASDAQ under the ticker symbol BEAM.
Beam Therapeutics has made 1 acquisition, including GuideTX.
Beam Therapeutics has 9 investors. Key investors include Sana Biotechnology, Arch Venture Partners, Eight Roads Ventures, Altitude Life Science Ventures, and Google Ventures.